FlowMedica, Inc.

Study: Benephit can help protect kidneys during coronary procedures

Published in Biotech Law Weekly, October 29th, 2004

Direct intrarenal drug delivery using the Benephit Infusion System can increase the beneficial effects of fenoldopam on the kidneys while minimizing systemic side effects in patients undergoing coronary procedures, according to important new clinical data reported at the Cardiovascular Research Foundation's annual scientific symposium, Transcatheter Cardiovascular Therapeutics.

Presented by Hooman Madyoon, MD, FACC, the data resulted from a physician-sponsored clinical study of the Benephit Infusion System developed by FlowMedica, Inc., a medical-device company pioneering targeted renal therapy.

Madyoon reported the results of a randomized,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Law Weekly

Source: Biotech Law Weekly (2004-10-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry